Track topics on Twitter Track topics that are important to you
Sweden aims to establish a new Centre for Advanced Medical Products (CAMP) as part of a SEK 320 million ($36.6 million), 8-year Swedish governmental initiative to position the country as a leading biologics developer. Swedish regenerative medicine firm Xintela, has been appointed a partner in the 6-year project to establish the CAMP cell and gene therapy research centre, with SEK 48 million ($5.5 million) in funding from the country’s innovation agency and research council, Vinnova and Vetenskapsrådet. Xintel said that as one of the CAMP initiative founders, it will work with Sweden’s universities, research institutes and with firms including AstraZeneca, GE Healthcare and Pfizer. Xintela will initially act as an advisor for development of the center, but in the longer term expects to benefit from emerging R&D. “It is gratifying that the Swedish government, Vinnova and Vetenskapsrådet acknowledge the huge potential of cell and gene therapy and ...NEXT ARTICLE
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...